DEA Acts Against Deadly Synthetic Drug Linked to 151 Overdose Deaths

September 1, 2018

N-Ethylpentylone is being passed off as the street drug ‘Ectasy’ or MDMA and is extremely dangerous, as N-Ethylpentylone is significantly more potent than MDMA and therefore very easy to overdose.

The Drug Enforcement Administration (DEA) has taken action against a dangerous designer synthetic cathinone linked to 151 overdose deaths in the United States between 2015 and 2018.

N-Ethylpentylone is a substituted cathinone and stimulant drug which was developed in the 1960s.

It has been reported as a novel designer drug in several countries including South Africa, New Zealand, the United States, and Australia, and has been linked to a number of overdose deaths and mass-casualty incidents.

N-Ethylpentylone is being illegally sold as the street drug ‘Ectasy’ or MDMA and is extremely dangerous, as N-Ethylpentylone is significantly more potent than MDMA and therefore very easy to overdose.

A common dose for MDMA is approximately 100 milligrams, whereas a dose for N-Ethylpentylone can be as little as 30 milligrams.

N-ethylpentylone in pill and crystal form found at #Boardmasters2018. These are potentially lethal. Looks and smells similar to MDMA. V long-lasting stimulant that can last for days and cause psychosis. Seek medical attention immediately if unwell. pic.twitter.com/eBQK3PR9pP

— The Loop (@WeAreTheLoopUK) August 12, 2018

Published in the Federal Register, DEA’s recent action puts N-Ethylpentylone into Schedule I of the Controlled Substances Act.

Schedule I substances refer to those with no legitimate, accepted medical or industrial use in the U.S.

Uttam Dhillon, Acting Administrator of the Drug Enforcement Administration

This action is based on a finding by the DEA Acting Administrator Uttam Dhillon that the placement of N-ethylpentylone in Schedule I is necessary to avoid an imminent hazard to the public safety.

DEA published its Notice of Intent to take this action in June 2018.

This temporary scheduling action lasts for 24 months, with an additional 12 months if necessary to conduct the necessary research to determine whether it should be controlled permanently.

This research will include an eight-factor analysis conducted by DEA and the Department of Health and Human Services.

We tested a gram of n-ethyl pentylone @Parklifefest yesterday – looks & smells same as MDMA crystal. Relieved this user didn’t take it. Take care & seek medical attention if unwell. #JustSayKnow #TimeToTest pic.twitter.com/mWVkPHvhPQ

— The Loop (@WeAreTheLoopUK) June 10, 2018

In 2017, DEA labs nationwide identified nearly 3,000 fentanyl and fentanyl-related compound exhibits, 922 synthetic cannabinoid exhibits, and 369 cathinone exhibits.

Of the 369 cathinone exhibits submitted to DEA labs for testing and identification, 201 of those were N-Ethylpentylone.

As a result of this order, the regulatory controls and administrative, civil and criminal sanctions applicable to Schedule I controlled substances will be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis or possess) or propose to handle N-ethylpentylone.

N-Ethylpentylone is a synthetic cathinone of the phenethylamine class and it is similar to cathinone, methamphetamine, MDMA, and other Schedule I and II substances.

It is highly likely that N-Ethylpentylone is abused in the same manner and by the same users as these substances.

Based on the overdose numbers since 2015, the abuse of N-Ethylpentylone, like that of the abuse of Schedule I synthetic cathinones and stimulant drugs, poses significant adverse health risks.

Adverse effects associated with N-ethylpentylone abuse include insomnia, hyperthermia, vomiting, agitation, disorientation, paranoia, abdominal pain, cardiac arrest, respiratory failure, coma, and death.

The DEA has taken this and other regulatory actions many times in previous years in response to the tremendous growth of designer synthetic drugs such as cathinones, cannabinoids, phenethylamines, and fentanyls and fentanyl analogues.

These substances are manufactured in overseas rogue labs, and often sold over the Internet using the Dark Web and other anonymous networks to evade law enforcement scrutiny.

They are not manufactured with any regard for human life or public safety.

Learn More about N-Ethylpentylone on the DEA Fact Sheet at

https://www.deadiversion.usdoj.gov/drug_chem_info/n-ethylpentylone.pdf

The Drug Enforcement Administration (DEA) has taken action against a dangerous designer synthetic cathinone linked to 151 overdose deaths in the United States between 2015 and 2018.

N-Ethylpentylone is a substituted cathinone and stimulant drug which was developed in the 1960s.

It has been reported as a novel designer drug in several countries including South Africa, New Zealand, the United States, and Australia, and has been linked to a number of overdose deaths and mass-casualty incidents.

N-Ethylpentylone is being illegally sold as the street drug ‘Ectasy’ or MDMA and is extremely dangerous, as N-Ethylpentylone is significantly more potent than MDMA and therefore very easy to overdose.

A common dose for MDMA is approximately 100 milligrams, whereas a dose for N-Ethylpentylone can be as little as 30 milligrams.

Published in the Federal Register, DEA’s recent action puts N-Ethylpentylone into Schedule I of the Controlled Substances Act.

Schedule I substances refer to those with no legitimate, accepted medical or industrial use in the U.S.

This action is based on a finding by the DEA Acting Administrator Uttam Dhillon that the placement of N-ethylpentylone in Schedule I is necessary to avoid an imminent hazard to the public safety.

DEA published its Notice of Intent to take this action in June 2018.

This temporary scheduling action lasts for 24 months, with an additional 12 months if necessary to conduct the necessary research to determine whether it should be controlled permanently.

This research will include an eight-factor analysis conducted by DEA and the Department of Health and Human Services.

In 2017, DEA labs nationwide identified nearly 3,000 fentanyl and fentanyl-related compound exhibits, 922 synthetic cannabinoid exhibits, and 369 cathinone exhibits.

Of the 369 cathinone exhibits submitted to DEA labs for testing and identification, 201 of those were N-Ethylpentylone.

N-Ethylpentylone is a synthetic cathinone of the phenethylamine class and it is similar to cathinone, methamphetamine, MDMA, and other Schedule I and II substances.

It is highly likely that N-Ethylpentylone is abused in the same manner and by the same users as these substances.

Based on the overdose numbers since 2015, the abuse of N-Ethylpentylone, like that of the abuse of Schedule I synthetic cathinones and stimulant drugs, poses significant adverse health risks.

Adverse effects associated with N-ethylpentylone abuse include insomnia, hyperthermia, vomiting, agitation, disorientation, paranoia, abdominal pain, cardiac arrest, respiratory failure, coma, and death.

The DEA has taken this and other regulatory actions many times in previous years in response to the tremendous growth of designer synthetic drugs such as cathinones, cannabinoids, phenethylamines, and fentanyls and fentanyl analogues.

These substances are manufactured in overseas rogue labs, and often sold over the Internet using the Dark Web and other anonymous networks to evade law enforcement scrutiny.

They are not manufactured with any regard for human life or public safety.

Learn More about N-Ethylpentylone on the DEA Fact Sheet at

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY